Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The association of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) is thought to be rare, and its optimal treatment is unknown. Of 130 consecutive patients with a diagnosis of PBC, we identified 12 cases (9.2%) of overlap syndrome (10 females, 2 males; median age, 50 years) strictly defined by the presence of at least two of the three recognized biochemical, serological, and histological criteria of each disease. One patient had initially pure PBC and developed AIH characterized by a flare of alanine transaminase (ALT) (1,330 IU/L; N < 35), elevated immunoglobulin G (IgG) (42 g/L; N < 14.0), and presence of anti-smooth muscle antibodies (ASMA) after 20 months of ursodeoxycholic acid (UDCA) therapy. A complete clinical and biochemical remission was achieved under combination of corticosteroids and UDCA. Eleven patients had features of both diseases at presentation: high serum levels of alkaline phosphatase (AP) (median: 280 IU/L; N < 100), ALT (140 IU/L), and IgG (30.8 g/L), presence of mitochondrial antibodies (n = 9) or ASMA (n = 9), florid bile duct lesions (n = 8), and moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (n = 11). UDCA (13-15 mg/kg/d) given alone in 5 patients induced a significant decrease in biochemical cholestasis but not in ALT levels, and liver fibrosis progressed in 3 patients. Corticosteroids given alone in 6 patients induced a significant decrease in ALT, IgG, and AP levels, but none had a biochemical normalization. The patients with persistently abnormal liver tests under either UDCA or corticosteroids received both UDCA and corticosteroids. A further marked biochemical improvement was observed, and all patients became asymptomatic. We conclude that, in patients with PBC: 1) overlap syndrome with AIH is not rare; 2) flares of AIH may occur either spontaneously or under UDCA; and 3) combination of UDCA and corticosteroids is required in most patients to obtain a complete biochemical response. Overlap syndrome may represent an important and unrecognized cause of resistance to UDCA in patients with PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The available data suggest that patients who fulfil the Paris criteria for the diagnosis of AIH either at presentation or during the course of their PBC may benefit from additional immunosuppression in the short-and medium-term [160,162,175,176].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [162]
In the citing paper
“A simplified AIH scoring system has more recently been developed, and, when applied to PBC patients, it identified fewer patients meeting probable AIH criteria than the older scoring system did (4% versus 12%).(125)(126)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [126]
In the citing paper
“Criteria have been proposed by the Paris group for ‘true’ PBC/AIH overlap,272 with two out of three of (a) ALT >5 x ULN, (b) IgG >2 x ULN or positive anti-SMA and (c) liver biopsy with ‘moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (interface hepatitis)’ being suggested as diagnostic of overlap in the context of a PBC diagnosis.”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [272]
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
Calmus, Y., Gane, P., Rouger, P., & Poupon, R. (1990) · Hepatology · doi:10.1002/hep.1840110104 · Cited by 303
Self-citationInvernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Research works printed but not linked: 2
- Shouval, 1979, Chronic active hepatitis with cholestatic features, Am J Gastroenterol, 72, 542
- Nakamura, 1995, Effect of ursodeoxycholic acid (UDCA) on patients with type 1 auto-immune hepatitis [Abstract], Gastroenterology, 107, 958A
Cited by
Items 101–200 of 743
Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant
Vleggaar, F. P., van Buuren, H. R., Zondervan, P. E., ten Kate, F. J. W., Hop, W. C. J., & the Dutch Multicentre PBC study group (2001) · Gut · doi:10.1136/gut.49.2.276 · Cited by 87
S2k Leitlinie Autoimmune Lebererkrankungen: AWMF-Reg. Nr. 021-27
Authors, Collaborators:, durch:, E. B., Deutsche Gesellschaft für Gastroenterologie, V. U. S. (. (., (DGIM), D. G. F. I. M., (DCCV), D. M. C. U. V., e.V., D. L., (DEGUM), D. G. F. U. I. D. M., (DGE-BV), D. G. F. E. U. B. V., (DGKJ), D. G. F. K. U. J., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-120199 · Cited by 90
Sahebjam, F., & Vierling, J. M. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0386-y · Cited by 92
“A retrospective analysis of the Paris criteria [104] showed a sensitivity of 92% and specificity of 97% for the diagnosis of AIH-PBC overlap [105].”
MethodKarlsen, T. H., Vesterhus, M., & Boberg, K. M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12581 · Cited by 86
Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis
Reshetnyak, V. I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i25.7683 · Cited by 86
Fibrosis in Autoimmune and Cholestatic Liver Disease
Penz-Österreicher, M., Österreicher, C. H., & Trauner, M. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.001 · Cited by 84
“Importantly, histological features canoverlapwith those of PSC or PBC and a careful histological examination is therefore mandatory [67,68].”
BackgroundFatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis
Quarneti, C., Muratori, P., Lalanne, C., Fabbri, A., Menichella, R., Granito, A., Masi, C., Lenzi, M., Cassani, F., Pappas, G., et al. (2015) · Liver International · doi:10.1111/liv.12560 · Cited by 80
“Patients with features such as high transaminase and IgG levels suggestive of autoimmune hepatitis/ PBC overlapping syndrome (8) were excluded from this study.”
BackgroundHeurgué, A., Vitry, F., Diebold, M.-D., Yaziji, N., Bernard-Chabert, B., Pennaforte, J.-L., Picot, R., Louvet, H., Frémond, L., Geoffroy, P., et al. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)89323-7 · Cited by 80
Ozaslan, E., Efe, C., Heurgué–Berlot, A., Kav, T., Masi, C., Purnak, T., Muratori, L., Ustündag, Y., Bresson–Hadni, S., Thiéfin, G., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.09.021 · Cited by 79
Bizzaro, N., Covini, G., Rosina, F., Muratori, P., Tonutti, E., Villalta, D., Pesente, F., Alessio, M. G., Tampoia, M., Antico, A., et al. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8234-y · Cited by 79
“However, the possibility of a subsequent appearance of overlap syndrome features should not be overlooked [ 48 ].”
BackgroundSoret, P., Lam, L., Carrat, F., Smets, L., Berg, T., Carbone, M., Invernizzi, P., Leroy, V., Trivedi, P., Cazzagon, N., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16336 · Cited by 78
Self-citationValidation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients #
Muratori, P., Granito, A., Pappas, G., & Muratori, L. (2009) · Hepatology · doi:10.1002/hep.22825 · Cited by 76
Levy, C., Naik, J., Giordano, C., Mandalia, A., O'Brien, C., Bhamidimarri, K. R., Schiff, E. R., & Martin, P. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.12.010 · Cited by 77
Gatselis, N., Zachou, K., Papamichalis, P. A., Koukoulis, G. Κ., Gabeta, S., Dalekos, G. N., & Rigopoulou, E. I. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.03.005 · Cited by 83
Efe, C., Pürnak, T., Özaslan, E., Özbalkan, Z., Karaaslan, Y., Altıparmak, E., Muratori, P., & Wåhlin, S. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.558114 · Cited by 86
The Overlap Syndromes of Autoimmune Hepatitis
Czaja, A. J. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2367-1 · Cited by 85
“The ‘‘Paris criteria’’ were promulgated in 1998, and they require the presence of at least two of three recognized hallmarks of each disease [102, 104].”
BackgroundMethodInfluentialTargeting hepatic stellate cells for cell-specific treatment of liver fibrosis
Beljaars, L., Meijer, D. K. F., & Poelstra, K. (2002) · Frontiers in bioscience · doi:10.2741/a917 · Cited by 77
Cirrhosis and autoimmune liver disease: Current understanding
Liberal, R., & Grant, C. R. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i28.1157 · Cited by 84
Difficult treatment decisions in autoimmune hepatitis
Czaja, A. J. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i8.934 · Cited by 78
Autoantibodies and overlap syndromes in autoimmune rheumatic disease
Jury, E. C., D’Cruz, D. P., & Morrow, W. J. (2001) · Journal of Clinical Pathology · doi:10.1136/jcp.54.5.340 · Cited by 74
Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis
Freedman, B. L., Danford, C. J., Patwardhan, V. R., & Bonder, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051449 · Cited by 79
“Joshi 2002 [8] Retrospective cohort study AIH-PBC (Paris criteria) [4].”
BackgroundMethodInfluentialYang, F., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Tang, R., Chen, X., Bian, Z., Zhang, H., Yang, Y., et al. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8516-5 · Cited by 71
Measurement of oxidative stress in human liver by EPR spin-probe technique
Valgimigli, L., Valgimigli, M., Gaiani, S., Pedulli, G. F., & Bolondi, L. (2000) · Free Radical Research · doi:10.1080/10715760000300721 · Cited by 71
Lupus Hepatitis and Autoimmune Hepatitis (Lupoid Hepatitis)
Adiga, A., & NUGENT, K. M. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.10.014 · Cited by 75
Autoimmune overlapping syndromes
Poupon, R. Y. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00092-8 · Cited by 73
“To the author’s knowledge, five cases of consecutive PBC and AIH have been reported [61,65–67] with close to 15 cases diagnosed during the last 5 years.”
BackgroundMethodInfluentialSelf-citationCurrent concepts in autoimmune hepatitis
Czaja, A. J. (2005) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32081-2 · Cited by 74
Prevalence of Primary Biliary Cirrhosis–Autoimmune Hepatitis Overlap Syndrome
Bonder, A., Retana, A., Winston, D. M., Leung, J., & Kaplan, M. M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.019 · Cited by 67
“Data included the following: (1) biochemical profile; (2) serum markers of autoimmunity such as antinuclear antibody, and antimitochondrial antibody; (3) immunoglobulin G or -globulin levels; and (4) the medications that were used to”
MethodAutoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management
Vierling, J. M. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.08.012 · Cited by 73
Sun, C., Xiao, X., Yan, L., Sheng, L., Wang, Q., Jiang, P., Lian, M., Li, Y., Wei, Y., Zhang, J., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.01.005 · Cited by 66
Autoimmune liver diseases in systemic rheumatic diseases
Wang, C., & Tsai, H. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i23.2527 · Cited by 73
van Gerven, N. M. F., de Boer, Y. S., Mulder, C. J. J., van Nieuwkerk, C. M., & Bouma, G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i19.4651 · Cited by 74
“are commonly applied.(57) In various reports AIH-PSC overlap syndrome has been described and is characterised by ANA and/or SMA seropositivity, hypergammaglobulinaemia and interface hepatitis - all features typical of “classical” AIH - in conjunction with cholestatic biochemical changes, frequently associated with inf…”
BackgroundCholestatic phenotypes of autoimmune hepatitis
Czaja, A. J. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.08.039 · Cited by 63
“Abnormal serum AP or GGT level Serum AP level>2-fold ULN in 21% of classical AIH and never >4-fold ULN (14) Serum GGT level never >5-fold ULN (38, 39) PBC, PSC, small duct PSC, AMA-negative PBC (4, 14, 16, 45)”
BackgroundMethodResultInfluentialWang, Q., Selmi, C. F., Zhou, X., Qiu, D., Li, Z., Miao, Q., Chen, X., Wang, J., Krawitt, E. L., Gershwin, M. E., et al. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.10.004 · Cited by 66
Papamichalis, P. A., Zachou, K., Koukoulis, G. K., Veloni, A., Karacosta, E. G., Kypri, L., Mamaloudis, I., Gabeta, S., Rigopoulou, E. I., Lohse, A. W., et al. (2007) · Journal of Autoimmune Diseases · doi:10.1186/1740-2557-4-3 · Cited by 63
Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis
Dalekos, G., Koskinas, J., & Papatheodoridis, G. V. (2018) · Annals of Gastroenterology · doi:10.20524/aog.2018.0330 · Cited by 72
“Regarding the AIH-PBC variant, its prevalence is about 10% in adults with PBC or AIH [61].”
BackgroundMethodMontano-Loza, A. J., Carpenter, H. A., & Czaja, A. J. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181587d18 · Cited by 62
Liaskos, C., Rigopoulou, E. I., Zachou, K., Georgiadou, S. P., Gatselis, N., PAPAMIHALI, R., & Dalekos, G. N. (2005) · Journal of Autoimmunity · doi:10.1016/j.jaut.2005.01.016 · Cited by 62
New scoring classification for primary biliary cholangitis–autoimmune hepatitis overlap syndrome
Zhang, W., De, D., Mohammed, K. A., Munigala, S., Chen, G., Lai, J., & Bacon, B. R. (2018) · Hepatology Communications · doi:10.1002/hep4.1148 · Cited by 67
“(22) Chazouilleres et al.(4) in 1998 suggested a Paris criteria classification that incorporated characteristics of both AIH and PBC to diagnose OS.”
BackgroundMethodInfluentialOptimizing Diagnosis From the Medical Liver Biopsy
Czaja, A. J., & Carpenter, H. A. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.031 · Cited by 67
Gheorghe, L., Iacob, S., Gheorghe, C., Iacob, R., Simionov, I., Vadan, R., Becheanu, G., Parvulescu, I., & Toader, C. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200406000-00012 · Cited by 60
Czaja, A. J., Shums, Z., & Norman, G. L. (2002) · Autoimmunity · doi:10.1080/0891693021000054101 · Cited by 60
Significance of antibodies to soluble liver antigen/liver pancreas: a large French study
Eyraud, V., Chazouilleres, O., Ballot, E., Corpechot, C., Poupon, R., & Johanet, C. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.01986.x · Cited by 58
“PBC criteria were as follows: (i) serum alkaline phosphatase (AP) levels at least two times the upper limit of normal values or serum g-glutamyl transpeptidase (GGT) levels at least five times the upper limit of normal values; (ii) a positive test for antimitochondrial antibodies (AMA); and (iii) a liver biopsy specim…”
BackgroundSelf-citationAutoimmune hepatitis: current challenges and future prospects
Aizawa, Y., & Hokari, A. (2017) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s101440 · Cited by 65
Oikawa, T., Takahashi, H., Ishikawa, T., Hokari, A., Otsuki, N., Azuma, M., Zeniya, M., & Tajiri, H. (2007) · Pathology International · doi:10.1111/j.1440-1827.2007.02129.x · Cited by 61
Development of autoimmune hepatitis in primary biliary cirrhosis
Gossard, A. A., & Lindor, K. D. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01538.x · Cited by 57
HLA and Autoimmune Digestive Disease: A Clinically Oriented Review for Gastroenterologists
Cassinotti, A., Birindelli, S., Clerici, M., Trabattoni, D., Lazzaroni, M., Ardizzone, S., Colombo, R., Rossi, E., & Porro, G. B. (2008) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.10 · Cited by 61
Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis
Sorrentino, P., Terracciano, L., D’Angelo, S., Ferbo, U., Bracigliano, A., Tarantino, L., Perrella, A., Perrella, O., Chiara, G. D., Panico, L., et al. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0249-x · Cited by 59
“We excluded all patients with a diagnosis of autoimmune PBC, based on the criteria described by others [14]: all patients with PBC as specified above with two or more of the following criteria were excluded from the analysis: (1) presence of ASMA or anti-LKM antibodies with a titer [1:80; (2) presence of ALT levels [5…”
MethodAutoimmune hepatitis and overlap syndromes
Dienes, H. P., Erberich, H., Dries, V., Schirmacher, P., & Lohse, A. W. (2002) · Clinics in Liver Disease · doi:10.1016/s1089-3261(02)00007-7 · Cited by 61
Review article: the management of autoimmune hepatitis beyond consensus guidelines
Czaja, A. J. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12381 · Cited by 55
Nakanuma, Y., Zen, Y., & Portmann, B. C. (2012) · MacSween's Pathology of the Liver · doi:10.1016/b978-0-7020-3398-8.00010-6 · Cited by 56
Burak, K. W., Urbanski, S. J., & Swain, M. G. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1010620122567 · Cited by 61
“The term AIC is used by many authors to describe patients with features of both PBC and AIH, but others argue that AIC is only a variant of PBC and the PBC-AIH overlap patients have distinct clinical features and responses to therapy (20).”
MethodZhang, W., Zhao, F.-R., Chen, J., & Chen, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092267 · Cited by 59
Tanaka, A., Ma, X., Yokosuka, O., Weltman, M., You, H., Amarapurkar, D. N., Kim, Y. J., Abbas, Z., Payawal, D. A., Chang, M.-L., et al. (2016) · Hepatology International · doi:10.1007/s12072-016-9767-9 · Cited by 55
Harms, M. H., Janssen, Q. P., Adam, R., Duvoux, C., Mirza, D., Hidalgo, E., Watson, C., Wigmore, S. J., Pinzani, M., Isoniemi, H., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15060 · Cited by 56
Shared Genetic Risk Factors in Autoimmune Liver Disease
Czaja, A. J., Santrach, P. J., & Moore, S. B. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1005670111068 · Cited by 57
“undergo transition into another type or who respond to medication typically effective in another form (17, 18).”
BackgroundEfe, C., Özaslan, E., Kav, T., Pürnak, T., Shorbagi, A., Özkayar, Ö., Berlot, A. H., Sökmensüer, C., & Muratori, P. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.09.006 · Cited by 54
Beuers, U. H. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.009 · Cited by 61
“In two more recent analyses, however, AIH-PBC overlap was found in 8% of 199 patients with AIH (nZ162) or PBC (nZ37) [1] and in 9% of 130 patients with PBC [5].”
BackgroundInfluentialPresence of antimitochondrial autoantibodies in patients with autoimmune hepatitis
Nezu, S., Tanaka, A., Yasui, H., Imamura, M., Nakajima, H., Ishida, H., & Takahashi, S. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04434.x · Cited by 52
Shackel, N. A., Jamias, J. D., Rahman, W. A., Prakoso, E., Strasser, S. I., Koorey, D. J., Crawford, M. D., Verran, D. J., Gallagher, J. P., & McCaughan, G. W. (2009) · Liver Transplantation · doi:10.1002/lt.21747 · Cited by 52
“In contrast, no relation between hepatitis and the level of serum HCV RNA was reported in 2 successive series.(20,21) In the present study, we were able to show that patients with a posttransplant peak viral load of 10(7) IU/mL within 1 year had worse patient and graft survival.”
ResultHarms, M. H., de Veer, R. C., Lammers, W. J., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Trivedi, P. J., Hirschfield, G. M., Pares, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319057 · Cited by 46
Liver transplantation for overlap syndromes of autoimmune liver diseases
Bhanji, R. A., Mason, A. L., Girgis, S., & Montaño‐Loza, A. J. (2012) · Liver International · doi:10.1111/liv.12027 · Cited by 51
“For example, between 5 and 9% of PBC patients have at least 2 of 3 criteria for PBC and AIH (5, 6) and these patients have an accelerated development of fibrosis (3).”
InfluentialObeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 53
“A few small case series describe complete biochemical response of most or all patients to the combination of UDCA and corticosteroids [68-72], including budesonide 3 mg twice or three times daily [73], either as first-line therapy in PBC--AIH overlap or after failure to respond to treatment for PBC or AIH alone.”
BackgroundThe Hepatitic/Cholestatic "Overlap" Syndrome: An Italian Experience
Muratori, L., Cassani, F., Pappas, G., Guidi, M., Mele, L., VERONESI, L., Lenzi, M., Bianchi, F. B., & Muratori, P. (2002) · Autoimmunity · doi:10.1080/0891693021000064272 · Cited by 51
Corpechot, C., Poujol‐Robert, A., Wendum, D., Galotte, M., Chrétien, Y., Poupon, R. E., & Poupon, R. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0918.x · Cited by 48
“All patients met the following criteria: (a) clinical, biochemical and histological features compatible with PBC; (b) exclusion of PBC-autoimmune hepatitis overlap syndrome according to previously defined criteria (13); (c) treatment with UDCA at a dose of 12–15mg/Kg/day for at least 2 years; (d) no other specific tre…”
BackgroundSelf-citationKitahata, S., Yamamoto, Y., Yoshida, O., Tokumoto, Y., Kawamura, T., Furukawa, S., Kumagi, T., Hirooka, M., Takeshita, E., Abe, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99314-9 · Cited by 48
Tanaka, A., Harada, K., Ebinuma, H., Komori, A., Yokokawa, J., Yoshizawa, K., Abe, M., Miyake, Y., Kikuchi, K., Ohira, H., et al. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00844.x · Cited by 47
Zhou, C., Jia, H., Liu, Y., Yu, M., Chang, X., Ba, Y., & Zou, Z. (2016) · Molecular BioSystems · doi:10.1039/c6mb00092d · Cited by 46
Clinical features and management of primary biliary cirrhosis
Crosignani, A. L., Battezzati, P. M., Invernizzi, P., Selmi, C. F., Prina, E., & Podda, M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3313 · Cited by 51
PRIMARY BILIARY CIRRHOSIS AND PRIMARY SCLEROSING CHOLANGITIS
Angulo, P., & Lindor, K. D. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70084-2 · Cited by 47
New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
Jhaveri, M., & Kowdley, K. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s113052 · Cited by 43
“12–15 According to Paris criteria, 12,16,17 an AIH–PBC overlap syndrome is accepted when two or three criteria of PBC as well as AIH are fulfilled.”
British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis
Gleeson, D. C., Bornand, R., Brownlee, A., Dhaliwal, H., Dyson, J. K., Hails, J., Henderson, P., Kelly, D. A., Mells, G. F., Miquel, R., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-333171 · Cited by 52
Efe, C., Özaslan, E., İmga, N. N., Tunca, H., Pürnak, T., & Altıparmak, E. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0996-9 · Cited by 45
“AIH was diagnosed based on the criteria of the International Autoimmune Hepatitis Group, and AIH/PBC overlap synrome was diagnosed according to the Chazouilleres et al. criteria [15, 16 ].”
MethodYokokawa, J., Saito, H., Kanno, Y., Honma, F., Monoe, K., Sakamoto, N., Abe, K., Takahashi, A., Yokokawa, H., & Ohira, H. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06018.x · Cited by 45
“criteria.(4) Both of these diagnostic criteria avoid the aforementioned drawback and have thus been used in most recent studies.”
BackgroundMethodResultInfluentialGoldstein, N. S., Soman, A., & Gordon, S. C. (2001) · American Journal of Clinical Pathology · doi:10.1309/vhhd-htru-n8j2-5x7r · Cited by 45
Tan, C., & Ho, J. M. S. (2001) · Liver Transplantation · doi:10.1053/jlts.2001.23792 · Cited by 44
Farias, A. Q., Gonçalves, L. L., Bittencourt, P. L., De Melo, E. S., Abrantes‐Lemos, C. P., Porta, G., Nakhle, M. C., Carrilho, F. J., & Cancado, E. L. R. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04130.x · Cited by 43
Autoimmune hepatitis: an approach to disease understanding and management
Corrigan, M., Hirschfield, G. M., Oo, Y. H., & Adams, D. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv021 · Cited by 48
Yamamoto, K., Terada, R., Okamoto, R., Hiasa, Y., Abe, M., Onji, M., & Tsuji, T. (2003) · Journal of Gastroenterology · doi:10.1007/s005350300006 · Cited by 47
A Spectrum of Histopathologic Findings in Autoimmune Liver Disease
Terracciano, L., Patzina, R. A., Lehmann, F. S., Tornillo, L., Cathomas, G., Mhawech, P., Vecchione, R., & Bianchi, L. (2000) · American Journal of Clinical Pathology · doi:10.1309/bhym-hmy5-vm1p-7geg · Cited by 43
“Periportal orcein-positive granules† 7 (70) 6 (60) 3 (27) 0 (0) Bile duct lesions, biliary type† 4 (40) 4 (40) 3 (27) 1 (9) Bile duct loss† 6 (60) 6 (60) 3 (27) 0 (0) Bile duct lesions, hepatitic type† 0 (0) 0 (0) 0 (0) 1 (9) Portal inflammation 8 (80) 9 (90) 11 (100) 9 (82) Lymphocytic aggregates† 3 (30) 3 (30) 2 (18…”
Overlap Syndrome of Autoimmune Hepatitis and Primary Biliary Cholangitis
To, U. K., & Silveira, M. G. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.010 · Cited by 43
Verdonk, R. C., Lozano, M., van den Berg, A. P., & Gouw, A. S. H. (2016) · Liver International · doi:10.1111/liv.13083 · Cited by 43
“These biochemical criteria were derived from the Paris Criteria (10).”
MethodSkin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review
Beretta‐Piccoli, B. T., Invernizzi, P., Gershwin, M. E., & Mainetti, C. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8649-9 · Cited by 47
Diagnosis of primary biliary cirrhosis
Hirschfield, G. M. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.10.005 · Cited by 43
“There is no universally agreed way to score/diagnose overlap but a commonly suggested means has been used to support the presence of a PBC/AIH overlap by looking for the presence of two of the three following features [65,66]: (1) ALT activity > 5 times upper limits of normal; (2) IgG 2 times upper limits of normal an…”
MethodMontaño‐Loza, A. J., & Corpechot, C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.062 · Cited by 44
Serum BAFF and APRIL levels in patients with PBC
Migita, K., Ilyassova, B., Kovzel, E. F., Nersesov, A., Abiru, S., Maeda, Y., Komori, A., Ito, M., Yano, K., Yatsuhashi, H., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.09.007 · Cited by 41
Therapy of autoimmune hepatitis
Strassburg, C. P., & Manns, M. P. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.08.003 · Cited by 45
Liver biopsy in primary biliary cirrhosis: Clinicopathological data and stage
Drebber, U., Mueller, J. J. M., Klein, E., Kasper, H. U., Schulze, F., Schardt, K., Quasdorff, M., Schulte, S., Odenthal, M., & Dienes, H. P. (2009) · Pathology International · doi:10.1111/j.1440-1827.2009.02405.x · Cited by 42
SUZUKI, Y., ARASE, Y., IKEDA, K., SAITOH, S., TSUBOTA, A., SUZUKI, F., KOBAYASHI, M., AKUTA, N., SOMEYA, T., MIYAKAWA, Y., et al. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03372.x · Cited by 40
Role of age in presentation, response to therapy and outcome of autoimmune hepatitis
Baven‐Pronk, M. A. M. C., Biewenga, M., van Silfhout, J. J., van den Berg, A. P., van Buuren, H. R., Verwer, B. J., van Nieuwkerk, C. M. J., Bouma, G., & van Hoek, B. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/s41424-018-0028-1 · Cited by 44
“All patients with anti-LKM antibodies — which were only present in the younger group, presumably with AIH type 2, which has a different clinical course — and patients with overlap syndromes, as de fi ned by the Paris criteria for PBC and by cholangiography criteria for PSC, were excluded 2,17,18 .”
Antibodies to soluble liver antigen in patients with various liver diseases: A multicentre study
Efe, C., Ozaslan, E., Wahlin, S., Purnak, T., Muratori, L., Quarneti, C., Yüksel, O., & Muratori, P. (2013) · Liver International · doi:10.1111/liv.12022 · Cited by 41
“AIH/PBC and AIH/PSC overlaps were diagnosed according to suggested criteria (13, 14).”
Zhao, J., Zhao, S., Zhou, G., Li, L., Guo, X., Mao, P., Zhou, X., Wang, H., Nan, Y., Xu, D., et al. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2010.539624 · Cited by 40
Hirschfield, G. M., Chazouillères, O., Cortez‐Pinto, H., Macedo, G., de Lédinghen, V., Adekunle, F., & Carbone, M. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1945919 · Cited by 42
“The presence of PBC with features of AIH can be approached diagnostically using the ‘Paris criteria’ [1,11].”
MethodSelf-citationAutoimmune Hepatitis: A Diagnostic and Therapeutic Overview
Mercado, L. A., Gil-Lopez, F., Chirilă, R. M., & Harnois, D. M. (2024) · Diagnostics · doi:10.3390/diagnostics14040382 · Cited by 42
“Criteria for AIH in PBC: In addition to interface hepatitis (mandatory), (1) serum ALT level ≥ 5-fold ULN and (2) serum IgG level >2-fold ULN or the presence of anti-smooth muscle antibodies (ASMAs) [26,27].”
BackgroundAutoantibodies in Autoimmune Hepatitis: Can Epitopes Tell Us about the Etiology of the Disease?
Christen, U., & Hintermann, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00163 · Cited by 45
“On the AIH side, the criteria comprise serum levels of alanine aminotransferase (ALT) that are elevated by at least five times the upper limit of normal values, serum levels of immunoglobulin G (IgG) that are at least two times higher than the upper limit of normal values, presence of AIH-typical autoantibodies, and a…”
BackgroundAutoimmune hepatitis in special patient populations
Czaja, A. J. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.09.011 · Cited by 43
“Patients with a more than two-fold elevation of the serum alkaline phosphatase level above the upper limit of the normal range (ULN) [57], destructive cholangitis (“florid duct lesion”) on histological examination [58], or cholangiographic features of PSC [59] can respond poorly to conventional corticosteroid regimens…”
BackgroundPrimary biliary cirrhosis and other ductopenic diseases
Burt, A. D. (2002) · Clinics in Liver Disease · doi:10.1016/s1089-3261(02)00010-7 · Cited by 39
“Assessing the incidence of PBC/AIH overlap is clearly influenced by the criteria used for the diagnosis; one recent study suggested that it occurred in almost 10% of PBC patients [60].”
AUTOANTIBODIES BY LINE IMMUNOASSAY IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
Saito, H., Takahashi, A., Abe, K., Okai, K., Katsushima, F., Monoe, K., Kanno, Y., & Ohira, H. (2012) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.58.107 · Cited by 39
Medical Treatment of Cholestatic Liver Disease
Paumgartner, G., & Pusl, T. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.013 · Cited by 39
Overlap Syndromes of Cholestatic Liver Diseases and Auto-Immune Hepatitis
Schramm, C., & Lohse, A. W. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:2:105 · Cited by 37
Primary biliary cirrhosis: new perspectives in diagnosis and treatment
Prince, M. I., & Jones, D. E. J. (2000) · Postgraduate Medical Journal · doi:10.1136/pmj.76.894.199 · Cited by 37
“AMA with an M2 distribution have been reported in patients with autoimmune hepatitis”
Metadata
- Authors
- Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- Corresponding author
- Chazouillères, Olivier
- Venue
- Hepatology
- Published
- 1998-08
- Volume
- 28
- Issue
- 2
- Pages
- 296-301
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2056147648
- Semantic Scholar
- e5878dda2aeaf614ad753e5c66ea3a752edfb605
- Cited by
- 746
- References
- 34
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 37 · 2023: 37 · 2022: 32 · 2021: 31 · 2020: 31 · 2019: 27 · 2018: 38 · 2017: 31 · 2016: 28 · 2015: 36 · 2014: 32 · 2013: 32 · 2012: 33
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6240 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, autoimmune hepatitis, overlap syndrome, ursodeoxycholic acid, corticosteroids, combination therapy, treatment resistance, anti-smooth muscle antibodies, antimitochondrial antibodies, cholestasis, liver fibrosis, IgG, anti-amyloid antibodies, remission, disease flares, bile duct lesions
- MeSH terms
- Adrenal Cortex Hormones, Adult, Aged, Cholagogues and Choleretics, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Liver Cirrhosis, Biliary, Male, Middle Aged, Syndrome, Ursodeoxycholic Acid, Treatment Outcome, Hepatitis, Autoimmune
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.